Myanmar

in page functions
[French]
Myanmar
Total population (2017) 54,836,254
Birth cohort (2017) 937,697
Surviving Infants (surviving to 1 year per year, 2017) 897,244
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 40/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 50/1000
World Bank Index, IDA (2015) 3.08
Gross Nation Income (per capita US$, 2015) 1,160
Co-financing group (2018) Preparatory transition
No. of districts/territories (2016) 330

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Myanmar

Type of support

Approvals

2001-2022 (US$)
(28 Mar 2018)

Commitments

2001-2022 (US$)
(28 Mar 2018)

Disbursements

2000-2018 (US$)
(28 Mar 2018)

% Disbursed

(28 Mar 2018)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $196,169,589 $269,249,623 $159,627,521
Cold Chain Equipment Optimisation Platform (CCEOP) $3,290,034 N/A
Health system strengthening (HSS 1) $32,770,639 $32,770,639 $29,773,024 91%
Health system strengthening (HSS 2) $20,000,000 $52,000,000
HepB mono (NVS) $13,833,610 $13,833,610 $13,833,610 100%
Immunisation services support (ISS) $7,707,080 $7,707,080 $7,707,080 100%
Injection Safety Devices (NVS) $1,478,000 $2,252,500 $1,911,444 129%
Injection safety support (INS) $2,083,978 $2,083,978 $2,083,978 100%
IPV (NVS) $5,445,620 $5,445,620 $3,011,620 55%
JEV (NVS) $6,546,000 $6,546,000 $7,155,505 109%
JEV - Operational costs (OPC) $9,125,500 $9,125,500 $9,125,500 100%
JEV-Routine (NVS) $545,000 $545,000 $561,350 103%
Measles (NVS) $3,014,453 $3,014,453 $3,189,530 106%
Measles-Rubella (NVS) $10,808,711 $10,808,711 $10,808,711 100%
MR - Operational costs (OPC) $11,357,500 $11,357,500 $11,357,500 100%
Penta (NVS) $33,507,407 $40,511,907 $28,901,578 86%
Pneumo (NVS) $31,419,591 $61,430,591 $23,680,591 75%
Vaccine Introduction Grant (VIG) $6,526,500 $6,526,500 $6,526,500 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Myanmar DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 90%
M:F sex ratio at birth (2017) 1.03
Household survey: DTP3 coverage for male (2008) 97.80%
Household survey: DTP3 coverage for female (2008) 97.90%
Household survey: Last DTP3 survey (2008) 98%
% districts achieving > 80% DTP3 coverage (2016) 88%
% districts achieving < 50% DTP3 coverage (2016) 5%
MCV WHO/UNICEF estimates (2016) 91%

Breakdown of support

Non-vaccine support Vaccine support
42% 58%
$66,573,582 $93,053,939

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Myanmar

05 February 2018

Rohingya refugee camps: diphtheria outbreak sends warning to all countries

Since November 2017, there have been around 5,000 suspected cases of diphtheria among the Rohingya refugees sheltering at Cox’s Bazar in eastern Bangladesh after fleeing their native Myanmar. In humanitarian crises, disease is often the first emergency but this outbreak took aid workers by surprise.

29 September 2017

Gavi item

900,000 vaccines 'en route' to Cox's Bazar to prevent cholera

Oral cholera vaccine will protect Rohingya refugees seeking shelter in Bangladesh as well as resident population.

01 July 2016

Close to 1 million Myanmar children to be protected with pneumococcal vaccine

With July’s launch of pneumococcal vaccine, which protects against the main cause of deadly pneumonia, Myanmar has introduced 9 vaccines against 10 diseases into its national immunisation programme.

close icon

modal window here